Key Clinical Publications

Insmed actively publishes and presents clinical data for ARIKAYCE.

Learn More


Insmed's management team is as well-rounded as it is experienced with a proven track record of success in drug delivery and commercialization. By combining a robust research background, industry expertise and sound business vision, we believe that our leadership is well prepared to guide the company into a promising future.

will lewisWill Lewis
President and Chief Executive Officer

Will joined Insmed in September 2012 as President and Chief Executive Officer and as a member of the Board of Directors. Will has more than 20 years of executive experience and a track record of success in the pharmaceutical and finance industries both in the US and internationally. Will is the former Co-Founder, President and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR). During his tenure at Aegerion, Will played a pivotal role in re-orienting the company's strategy to focus on orphan disease indications enabling Aegerion to go public in one of the best performing IPOs of 2010. Prior to Aegerion, Will spent 10 years working in the U.S. and Europe in investment banking for JP Morgan, Robertson Stephens and Wells Fargo. During his time in banking, he was involved in a broad range of domestic and international capital raises and advisory work valued at more than $20 billion. Will serves as a member of the Supervisory Board of uniQure N.V. (Nasdaq: QURE). Will also serves as a member of the Board of BioNJ, as a member of the Board of Directors of Oberlin College, and as a member of the Visiting Committees of the Weatherhead School of Management of Case Western Reserve University and The Hawken School. Will holds a Bachelor of Arts degree cum laude from Oberlin College and a Master of Business Administration/Juris Doctor with Honors from Case Western Reserve University. Prior to attending graduate school he worked in the Foreign Service for the US Government.

andy drechslerAndrew Drechsler
Chief Financial Officer

Andy joined Insmed as Chief Financial Officer in November 2012. He offers 15 years of financial and operational leadership experience in both public and private life sciences companies. Andy joins Insmed from VaxInnate Corporation, a privately held clinical-stage biotechnology company developing vaccines for infectious diseases, where he was Chief Financial Officer. During his five years with VaxInnate, he led multiple financing transactions totaling more than $55 million. Previously, he was Chief Financial Officer of publicly-traded Valera Pharmaceuticals where he helped raise $35 million through an initial public offering in 2006, completed a licensing and investment agreement with a partner for two products and worked with senior management to build a commercial team. Andy was part of the team that negotiated the sale of the company to Indevus Pharmaceuticals in 2007 in a transaction valued at $150 million. His public company and financial reporting duties have also included serving as controller for a variety of companies, including Abbott Laboratories’ Point of Care Division, which was publicly-traded as i-Stat Corporation prior to being acquired by Abbott, and Biomatrix, Inc., which was publicly-traded prior to being acquired by Genzyme. He graduated Magna Cum Laude from Villanova University with a BS in Accounting and received his certified public accountant license in New Jersey. 

matt paulsMatthew Pauls
Chief Commercial Officer

Matthew joined Insmed as Chief Commercial Officer in April 2013. He has substantial commercial and general management experience, with P&L responsibility, and has led the launch of multiple products in the global pharmaceutical and medical device markets. Prior to joining Insmed, he was with Shire Pharmaceuticals, a publicly traded specialty biopharmaceutical company, most recently as Senior Vice President, Head of Global Commercial Operations, Shire Regenerative Medicine. In this role, Matthew led the global commercial function of a business unit with a staff of approximately 300 including a 200-person US sales team and $160 million in sales. Previously he was Vice President, General Manager, Shire Specialty Pharmaceuticals Behavioral Health Business Unit, where he had P&L responsibility for the multi-billion dollar ADHD portfolio of Vyvanse in the US and Intuniv globally. Previously, Matthew served in various marketing and management roles with two leading publicly traded pharmaceutical companies: Bristol-Myers Squibb Company and Johnson & Johnson, Inc. Matthew earned his JD from Michigan State University College of Law and his MBA and BS degrees from Central Michigan University.

christine pellizzariChristine Pellizzari
General Counsel & Corporate Secretary

Christine Pellizzari joined Insmed in July 2013. She brings nearly 20 years of senior-level leadership experience in the global biotechnology and pharmaceutical industry.  Most recently, Ms. Pellizzari served as Executive Vice President, General Counsel and Secretary of Aegerion Pharmaceuticals, Inc., a publicly traded company developing therapies for rare diseases.  Among her accomplishments and responsibilities at Aegerion, Ms. Pellizzari oversaw all the legal aspects of that company’s successful IPO and secondary public offering and served as a member of the Executive Management Committee.  Prior to joining Aegerion, Ms. Pellizzari served as Senior Vice President, General Counsel and Secretary of Dendrite International, Inc., a publicly traded company that provided sales effectiveness, promotional and compliance solutions to the global pharmaceutical industry.  She was a member of the company's Executive Operations Management Committee and helped lead many critical initiatives during her 9 year tenure, including the sale of the company to Cegedim S.A. in May, 2007.  Ms. Pellizzari joined Dendrite from the law firm of Wilentz, Goldman & Spitzer where she specialized in health care transactions and related regulatory matters. Before joining Wilentz, Ms. Pellizzari served as law clerk to the Honorable Reginald Stanton, Assignment Judge for the Superior Court of New Jersey. Ms. Pellizzari received her BA, cum laude, from the University of Massachusetts, Amherst and her JD from the University of Colorado, Boulder.

walter perkinsWalter Perkins, PhD
Chief Technology Officer

Walter joined Insmed in December 2010 in connection with the business combination between Insmed and Transave. Prior to this, Walter joined Transave in 2002 and served as Chief Technology Officer. Walter has over 20 years experience utilizing lipid-based drug delivery systems and has authored over 66 scientific publications and patent applications. Prior to joining Transave, Walter spent 15 years with The Liposome Company (later a part of Elan Drug Delivery). At The Liposome Company, Walter was involved in the design of several lipid-based drug delivery systems, including an artificial lung surfactant formulation, and helped in the characterization, development and launch of the company's two commercial products Abelcet® and Myocet®. As a part of Elan's Drug Delivery Division, he played a lead role in the implementation of liposome technology in both inter-divisional projects and corporate partnerships. Walter received his bachelor's and doctoral degrees in Biophysical Chemistry from the University of Virginia where he studied the physical and electrical properties of liposomal membranes.

Nicole SchaefferS. Nicole Schaeffer
Senior Vice President, Human Resources and Corporate Services

Ms. Schaeffer joined Insmed in October 2012. She brings more than 20 years of experience in Human Resources, organizational development, corporate operations and building life science organizations. Most recently Ms. Schaeffer served as Senior Vice President, Administration and Human Resources, for Amicus Therapeutics where she was responsible for the human resources, facilities and IT functions. While at Amicus, Ms. Schaeffer was responsible for the organizational growth and development of this high performing company from its earliest stages to its current position as a late-stage clinical company. During this time, she focused on developing a culture of excellence to support that growth. Prior to Amicus, she served as Senior Director, Human Resources, for three portfolio companies of Flagship Ventures, a venture capital firm, and in that capacity she managed human resources for three life sciences companies. She has also held HR leadership positions with Oak Industries and EMC Corporation. Ms. Schaeffer received her BA from the University of Rochester and her MBA from Boston University.

Lilia Arvizu
Vice President of Global Medical Affairs

Lilia Arvizu, PhD, joined Insmed as Vice President of Global Medical Affairs in June, 2014. Her career in the biopharmaceutical industry encompasses over 15 years of Medical Affairs and Leadership experience. Lilia has held positions of increased responsibility, including setting strategic direction, managing key initiatives, and developing operations and processes across all functions of Medical Affairs nationally and globally. Therapeutically, Lilia has supported a wide range of products in the orphan-disease space throughout the pre- and post-launch continuum. Prior to joining Insmed, Lilia served as Senior Director of Medical Affairs at Hyperion Therapeutics; a publicly traded company that focuses on ultra-rare, genetic disorders. Additionally, Lilia spent 6 years at Genzyme where she fulfilled responsibilities as Director of Medical Affairs managing the MSL Team, and spearheading the development of Medical Communications and the Investigator Sponsored Trials (IST) program. Before Genzyme, Lilia held positions at EMD-Serono, as Director of Scientific Communications and Medical Review, and as Director of Medical Affairs, in the Neurology Division. She also held various positions in Medical Affairs at Bristol-Myers Squibb and Abbott Laboratories. Lilia received a Master’s Degree, and a PhD degree from the University of Texas at Austin. Her interests included mass media research, neuroscience, and cognitive psychology. After completing her doctoral training, Lilia worked at the University of Miami, in the Department of Behavioral Neurology. Her clinical work and scientific research concentrated in Alzheimer’s disease and other neuro-degenerative disorders, including posterior cortical atrophy, multiple sclerosis, Parkinson’s disease, ALS and stroke.

peggy berryPeggy Berry
Vice President of Regulatory Affairs

Peggy Berry joined Insmed in February 2014 as Vice President of Regulatory Affairs. Peggy is responsible for the development and implementation of global regulatory strategies and the management and oversight of the Regulatory Affairs department. Prior to joining Insmed, she held a variety of senior level positions in Amarin, Dyax, AstraZeneca, and Dey Pharma. She has also held roles at two clinical contract research organizations within Regulatory Affairs (ILEX Oncology and Cato Research Ltd.) and has worked in review divisions at the FDA. In addition, Ms. Berry consults for a number of companies in the regulatory and quality area and is active in the Regulatory Affairs Professionals Society. She is the editor of the 2010 book “Choosing the Right Regulatory Career” (RAPS, MD) and author of the 2011 book “Communication & Negotiation” (RAPS, MD). Peggy has an MBA from The University of Phoenix and a B.S. in Biology from Charter Oak State College in Connecticut.

peter clarkePeter Clarke, PhD
Vice President, Technical Operations

Peter joined Insmed as Vice President of Manufacturing in April 2013. He offers more than 28 years in the biopharmaceutical industry in positions of increasing responsibility in both Europe and the US. He has worked for biotech start-ups bringing novel products to market as well as with multi-national companies such as Bayer being responsible for the manufacture and supply of established medicinal products. Peter has led international teams that have developed manufacturing processes and their associated analytical methods for several classes of biopharmaceuticals. He has been the technical lead in facility design, commissioning, validation and start-up and has been responsible for the technical content of submissions to the FDA, EMA and other regulatory agencies. Prior to joining Insmed, Peter was Group VP and Chief Technology Officer of Savient Pharmaceuticals, where he was responsible for manufacturing and supply chain management of Krystexxa and Oxandrin. Previously, he was VP Production and Technical Processes for Introgen Therapeutics where he led the manufacturing team for Advexin and liposome encapsulated DNA vectors. Peter earned his PhD in Microbial Physiology from London University.

john gollJohn Goll
Vice President, Corporate Controller

John joined Insmed as Vice President, Corporate Controller in March 2014. He brings over 20 years of senior-level financial and accounting experience in the global pharmaceutical industry. John joins Insmed from Warner Chilcott plc, a publicaly traded global specialty pharmaceuticals company (acquired by Actavis plc in October 2013) focused on the women’s healthcare, gastroenterology, urology and dermatology segments of the branded pharmaceuticals market, where he was VP, Controller. During his over eight years with Warner Chilcott, his responsibilities included global inrernal and external financial reporting and all SEC filings. He played an integral role in building a global finance team and his work included many important initiatives, including the company’s successful $1.1 billion IPO in 2006 and multiple follow-on secondary offerings and financings, as well as, the transformative acquisition of P&G’s global pharmaceuticals business in 2009. Previously, he was Director, Financial Planning & Analysis at Alpharma Inc., a publicly-traded human and animal pharmaceuticals company and was a Senior Accountant at RD Hunter & Company LLP, CPAs. He graduated from The College of New Jersey with a BS in Accounting and holds an MBA in Finance from Fairleigh Dickinson University. John is a licensed certified public accountant in New Jersey.

wes kaupinenWes Kaupinen
Vice President of Corporate Development and Commercialization

Wes Kaupinen joined Insmed in August 2013 as Vice President of Corporate Development and Commercialization, bringing extensive experience in corporate strategy, business development, finance, and sales management and operations. Prior to joining Insmed, Wes was a senior investment professional with Quaker Partners, a healthcare venture capital and growth equity firm, where he led and was involved in a number of public and private investments in emerging growth companies in the biotech, specialty pharma, and medical device sectors. While with Quaker, Wes served as a member of the Board of Directors of TELA Bio and Intact Vascular, and was closely involved in Quaker’s investments in NovaSom, Horizon Pharma, and Achillion Pharmaceuticals. Wes previously held various sales and marketing roles at Synthes and J&J Cordis Cardiology, including serving as part of the senior sales leadership team for Synthes U.S. Trauma Division. Prior to joining Synthes, Wes worked in the Healthcare Group at Apax Partners, a global private equity firm, where he worked closely on Apax’s investments in Skinmedica (sold to Allergan) and ESP Pharma (sold to Protein Design Labs). Wes began his career in the Life Sciences Group at Robertson Stephens where he focused on M&A and corporate finance. Wes has an MBA from The Wharton School of The University of Pennsylvania where he was the recipient of the William L. Kissick M.D. Scholarship Award, and a B.A. in Economics from The University of Virginia.

Mark QuigleyMark A. Quigley, Ph.D.
Vice President Quality Assurance

Mark joined Insmed in September 2013 as Vice President Quality Assurance. Mark brings over 30 years of pharmaceutical industry experience spanning a number of operational areas including clinical research, medical affairs, pharmacovigilance, regulatory affairs and quality assurance. Prior to joining Insmed, Mark was the Executive Vice President of Quality and Compliance at Icon PLC, a contract research organization (CRO), where he was responsible for quality assurance and training for all divisions of the company globally. Prior to Icon PLC, Mark held the position of Global Vice President of Quality & Compliance for Sanofi. Mark began his career as a hospital pharmacist in a large teaching hospital, where he lead the intravenous admixture program and performed pharmacoeconomic evaluations along with the traditional activities. He left to join Marion Laboratories in 1980 as a Senior Scientist in clinical research. From there, Mark progressed to head the pharmacovigilance organization, and following merger activity, the Senior Director of U.S. Drug Regulatory Affairs for Marion Merrell Dow. He became Vice President of Global Regulatory Compliance and Product Surveillance with Hoechst Marion Roussel and then Global Head - Vice President of Global Quality Assurance/Compliance and Regulatory Chemistry Manufacturing and Controls for Aventis. During his career he was involved with numerous products developed and commercialized in countries worldwide and was directly involved with regulatory agencies. Mark holds a Bachelor of Science degree in Pharmacy, a Master of Science in Pharmaceutical Science and a Ph.D. in Pharmaceutical Science with a minor in Quantitative Analysis, and is a certified fraud examiner (CFE). He also served as an adjunct assistant professor of Pharmacy at the University of Missouri where he was involved with graduate students and sat on Ph.D. research committees.

renu guptaRenu Gupta, MD
Special Advisor to the CEO

Renu joined Insmed in December 2010 in connection with the business combination between Insmed and Transave. Renu has more than 25 years of development, regulatory and senior management experience with the biopharm industry. Previously Renu has served as the Executive Vice President Development and Chief Medical Officer of Transave, Inc. since September 2006, and has been a Director of the UK subsidiary, Transave Inhalation Biotherapeutics as of May 2008. From May 2003 to August 2006, she held the position of Senior Vice President Development at Antigenics, Inc. Prior to that, she served at Novartis as Vice President and Head of US Clinical Research and Development and Global Head of Cardiovascular, Metabolics, Endocrine and Gastroenterology Research. Renu also spent almost 10 years at Bristol-Myers Squibb, where she was responsible for clinical research, business development and global development and marketing strategy for infectious diseases and immunology. She received her bachelor and medical degrees from the University of Zambia and completed her medical and post-doctoral training at Albert Einstein Medical Center, the Wistar Institute of Anatomy and Biology, Children's Hospital of Philadelphia, and the University of Pennsylvania, where she was Adjunct Assistant Professor until 1997. Her work has been published in leading peer-reviewed journals and she has been active in numerous relevant academic and professional societies. Renu is a founding member of the Industrial Management Board at the Harvard Medical School, served as Chair of the Medical Advisory Council for Antigenics, past member of the Scientific Advisory Board at Cerimon Pharmaceuticals, and the Institute of Medicine Forum on Emerging Infections, and is a Board Member of Aim at Melanoma, formerly Charlie Guild Melanoma Foundation.


(liposomal amikacin
for inhalation)

arikace nebulizer

A differentiated, once-a-day inhaled antibiotic engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the efficacy, safety and convenience of treatment for patients.

Learn More